Has Amir Jazaeri, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,945 in general payments to Amir Jazaeri, MD across 34 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amir Jazaeri, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amir Jazaeri, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amir Jazaeri, MD

Obstetrics & Gynecology · Houston, TXNPI 1588784193

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $13,190 of the $16,945 with a category attached, or 77.8%. 18 manufacturers reported payments, led by Eisai Inc. at 26.3% of the total. Reporting peaked in 2021 at $7,328 and has fallen 95.9% since, to $299 in 2025. Among obstetrics & gynecology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$16,945in general payments, 2019–2025

Across 34 payments — averaging $498.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Eisai Inc.$4K
E.r. Squibb & Sons, L.L.C.$3K
Alkermes, Inc.$2K
GSK$2K
Astrazeneca UK Limited$1K
Merck Kgaa$690
plus $3K from 12 others

$19,483,115in research payments, 2019–2025

Across 101 payments — averaging $192,902 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Merck$12.5M
GSK$2.6M
AstraZeneca$2.1M
Clinigen, Inc.$953K
Macrogenics, Inc.$894K
Iovance Biotherapeutics, Inc.$360K
plus $195K from 4 others

What the payments were for

Consulting fees$13,19078%
Speaking & faculty fees$1,2037%
Travel & lodging$1,0876%
Food & beverage$1,4559%
Education$110%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Eisai Inc.	3	$4,452
E.r. Squibb & Sons, L.L.C.	3	$3,360
Alkermes, Inc.	2	$2,185
GSK	1	$2,175
Astrazeneca UK Limited	1	$1,167
Merck Kgaa	1	$690
Intuitive Surgical	3	$628
Stryker	2	$626
Pacira Pharmaceuticals Incorporated	1	$513
Johnson & Johnson	3	$200
AstraZeneca	2	$180
Clovis Oncology, Inc.	3	$168
Genentech USA, Inc.	2	$156
Verastem, Inc.	2	$145
Merck	2	$117
Macrogenics, Inc.	1	$72
Immunogen, Inc.	1	$63
AbbVie	1	$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,945 in reported general payments places this provider in the 95th percentile of 3,099 obstetrics & gynecology providers in Texas.

See all obstetrics & gynecology providers in Texas →

Medicare billing

Part B allowed, 2024

$50,230

Medicare patients

147

Services billed

369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	12	$7,954
Ondansetron Hcl	38	$189
Prochlorperazine Maleate	15	$189
Tamoxifen Citrate	11	$105

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Houston

George KuhnHouston$244K
Daisy AyimHouston$188K
Shannon WestinHouston$176K
Asha BhalwalHouston$151K
Nicole TranHouston$133K
Sandra HurtadoHouston$123K
Alvaro MontealegreHouston$92K
Patti RossHouston$72K
Damla KarsanHouston$58K
Christopher JayneHouston$52K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →